Medicinal Cannabis Matters: Friday Roundup - 2 October 2026

No New Safety Concerns as Medicinal Cannabis Use Grows

Denmark’s medicinal cannabis programme has continued to expand, with the number of patients collecting prescriptions increasing by 54% in 2025 compared with the previous year.

According to the Danish Medicines Agency’s annual safety report, 2,465 patients collected medicinal cannabis prescriptions during 2025, with 22,410 prescriptions dispensed. The country’s pilot programme, which began in 2018, became a permanent programme on 1 January 2026.

Despite the increase in use, the regulator identified no new safety concerns during 2025.

The findings highlight the importance of continued monitoring as more patients access medicinal cannabis and more real-world safety data becomes available.

What Should UK Patients Know About Medicinal Cannabis Vaporisers

For patients prescribed cannabis flower for inhalation, understanding how to use a vaporiser correctly is an important part of treatment.

A medicinal cannabis vaporiser heats prescribed flower without burning it, producing a vapour containing cannabinoids such as THC and CBD. This is different from smoking, which involves combustion and produces smoke and other by-products.

Cannabis Health has published a comprehensive guide covering the different types of devices available and some of the practical considerations for patients.

One important point is that not every device described as a ‘vape’ is the same. Dry-herb vaporisers are designed to heat prescribed cannabis flower, while other devices may use liquid cannabis extracts or vape liquids. Oral cannabis oils should not be placed into a vaporiser unless the particular medicine has specifically been formulated and prescribed for inhalation using a compatible device.

Temperature can also influence how much of a medicine is delivered. A 2025 review referenced in the guide suggests a starting range of around 180–200°C, although the appropriate temperature will depend on the individual patient, product and device. If vapour causes respiratory irritation, the review suggests that a lower temperature or an alternative route of administration may be considered.

There is no single temperature or device that is right for every patient. Prescribed cannabis should always be used according to the instructions provided by the prescribing team and the manufacturer’s guidance for the device.

What Does the Evidence Tell Us about Medicinal Cannabis and Endometriosis

Endometriosis can cause persistent pelvic pain and a wide range of other symptoms, and many people continue to experience difficulties despite existing treatment options.

As interest in medicinal cannabis grows, researchers are examining whether cannabinoids such as THC and CBD could have a role in managing some of the symptoms associated with the condition.

The available evidence includes reports of improvements in pelvic pain, sleep, gastrointestinal symptoms and quality of life among some patients using medicinal cannabis. A two-year study from the UK Medical Cannabis Registry also reported sustained improvements in pain, quality of life, anxiety and sleep among patients with endometriosis.

For patients living with persistent symptoms, continued research could help provide a clearer understanding of where medicinal cannabis may have a role within personalised treatment.

As more patients access medicinal cannabis, real-world data can help researchers and regulators understand how these medicines are being used and monitored in practice. At the same time, high-quality clinical research remains important in helping us understand effectiveness and which treatments may be most appropriate for individual patients.

At Medicann, we believe patients should have access to clear, evidence-led information and personalised clinical support throughout their treatment journey.

If you’re considering whether medicinal cannabis may be suitable for your condition, you can check your eligibility online in just two minutes.

Disclaimer: This blog post and the following featured articles are for information only and any articles on external platforms may be amended at any time. Articles that we refer to in our weekly roundup do not reflect the views of Medicann.